Parsons Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Parsons Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.86M	Buy	9,779 +138	+1%	+$61.2K	0.22%	100
2026 Q1	$4.31M	Buy	9,641 +150	+2%	+$69.9K	0.2%	107
2025 Q4	$4.3M	Sell	9,491 -395	-4%	-$170K	0.24%	93
2025 Q3	$3.87M	Sell	9,886 -542	-5%	-$227K	0.22%	106
2025 Q2	$4.64M	Buy	10,428 +2,660	+34%	+$1.23M	0.29%	79
2025 Q1	$3.77M	Buy	7,768 +735	+10%	+$343K	0.21%	100
2024 Q4	$2.83M	Buy	7,033 +1,521	+28%	+$705K	0.15%	128
2024 Q3	$2.56M	Buy	5,512 +250	+5%	+$120K	0.16%	135
2024 Q2	$2.47M	Buy	5,262 +2,591	+97%	+$1.12M	0.17%	130
2024 Q1	$1.12M	Buy	2,671 +1,884	+239%	+$796K	0.08%	220
2023 Q4	$320K	Buy	787 +100	+15%	+$36.9K	0.02%	365
2023 Q3	$239K	Hold	687	–	–	0.02%	383
2023 Q2	$242K	Sell	687 -2	-0.3%	-$674	0.02%	387
2023 Q1	$217K	Buy	+689	New	+$207K	0.02%	398
2021 Q4	–	Sell	-1,268	Closed	-$230K	–	442
2021 Q3	$230K	Sell	1,268 -1,420	-53%	-$277K	0.02%	401
2021 Q2	$542K	Sell	2,688 -723	-21%	-$151K	0.04%	283
2021 Q1	$733K	Sell	3,411 -2,618	-43%	-$575K	0.06%	236
2020 Q4	$1.43M	Sell	6,029 -70	-1%	-$16.1K	0.12%	159
2020 Q3	$1.66M	Buy	6,099 +412	+7%	+$114K	0.16%	129
2020 Q2	$1.65M	Buy	5,687 +345	+6%	+$93.5K	0.18%	118
2020 Q1	$1.27M	Buy	+5,342	New	+$1.23M	0.16%	132

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Parsons Capital Management's VRTX Position: Q2 2026 in Review

Parsons Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, buying an estimated $61.2K and bringing the position to 9,779 shares worth $4.86M. The position accounts for 0.22% of the portfolio, ranked #100.

Parsons Capital Management first reported a position in VRTX in Q1 2020 and has held it in 21 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Parsons Capital Management held 9,779 shares of Vertex Pharmaceuticals worth $4.86M as of Q2 2026.
Parsons Capital Management bought 138 Vertex Pharmaceuticals shares in Q2 2026, an estimated $61.2K.
Vertex Pharmaceuticals made up 0.22% of Parsons Capital Management's portfolio in Q2 2026, its #100 holding.
Parsons Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.